title: Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
abstract: BACKGROUND
  Lanreotide Autogel/Depot effectively controls symptoms in patients with carcinoid syndrome associated with neuroendocrine tumours. Data on patient-reported outcomes are sparse.
  
  
  OBJECTIVE
  To evaluate the effect of lanreotide on patient-reported outcomes (PROs) with carcinoid syndrome.
  
  
  METHODS
  This was an international, open-label, observational study of adults with neuroendocrine tumours and history of diarrhoea, receiving lanreotide for >3 months for relief of carcinoid syndrome symptoms. The primary PRO measure was satisfaction with diarrhoea control. Secondary PRO measures included severity, change in symptoms and impact on daily life of diarrhoea; and patient satisfaction with flushing control.
  
  
  RESULTS
  Of 273 patients enrolled, 76% were 'completely' or 'rather' satisfied with diarrhoea control; 79% reported improvement in diarrhoea with lanreotide. The proportion of patients with 'mild', 'minimal', or 'no diarrhoea' increased from 33% before treatment to 75% during treatment; 75% were unconcerned about the impact of diarrhoea on daily life. Satisfaction with flushing control amongst patients with significant flushing at treatment initiation was 73%.
  
  
  CONCLUSIONS
  Lanreotide treatment was associated with improvements in symptoms as well as a range of PROs in patients with neuroendocrine tumours and carcinoid syndrome (ClinicalTrials.gov: NCT01234168).
authors.affiliation: Beaujon Hospital and Paris Diderot University, Clichy, France. Electronic address: philippe.ruszniewski@bjn.aphp.fr.
authors.forename: Philippe
authors.initials: P
authors.lastname: Ruszniewski
authors.affiliation: Institute of Cancer Studies, University of Manchester/The Christie NHS Foundation Trust, Manchester, UK.
authors.forename: Juan W
authors.initials: JW
authors.lastname: Valle
authors.affiliation: Edouard-Herriot Hospital, Hospices Civils de Lyon, Lyon, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Lombard-Bohas
authors.affiliation: Department of Obesity and Endocrinology and Liverpool ENETS Centre of Excellence, University Hospital Aintree and University of Liverpool, Liverpool, UK.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Cuthbertson
authors.affiliation: Freeman Hospital, Newcastle-upon-Tyne, UK.
authors.forename: Petros
authors.initials: P
authors.lastname: Perros
authors.affiliation: Teaching Hospital Plzen, Plzen-Bory, Czech Republic.
authors.forename: Luboš
authors.initials: L
authors.lastname: Holubec
authors.affiliation: Ospedale Sant' Andrea, Rome, Italy.
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Delle Fave
authors.affiliation: Saint André Hospital, Bordeaux, France.
authors.forename: Denis
authors.initials: D
authors.lastname: Smith
authors.affiliation: CHU Timone, Marseille, France.
authors.forename: Patricia
authors.initials: P
authors.lastname: Niccoli
authors.affiliation: Ipsen, Boulogne-Billancourt, France.
authors.forename: Pascal
authors.initials: P
authors.lastname: Maisonobe
authors.affiliation: Ipsen, Boulogne-Billancourt, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Atlan
authors.affiliation: Royal Free Hospital, London, UK.
authors.forename: Martyn E
authors.initials: ME
authors.lastname: Caplin
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D003967:Diarrhea / Q000209:etiology*; D005260:Female; D005483:Flushing / Q000209:etiology*; D006801:Humans; D038622:Internationality; D008297:Male; D008303:Malignant Carcinoid Syndrome / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D000071066:Patient Reported Outcome Measures; D017060:Patient Satisfaction; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D011446:Prospective Studies; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin
keywords: Diarrhoea; Neuroendocrine tumour